Spencer Philips Hey, Ph.D.
Dr. Hey works on ethical, policy, and methodological issues at the intersection of philosophy of science and biomedical research ethics. He has published on a variety of topics, including the ethics of placebo-controlled trials, adaptive randomization, risk minimization in early-phase human trials, discordant evidence, complexity and coordination problems in cancer biomarker research, and why clinical investigators ought to make explicit likelihood predictions in their research protocols. He has also developed a graph-theoretic approach to representing medical research programs. Published examples of the approach thus far have included research programs in tuberculosis and diagnostic development in precision medicine, but more examples--particularly in cancer drug development--will be appearing in print soon.
Dr. Hey received his Ph.D. in philosophy from the University of Western Ontarioand a B.A. in philosophy from the University of Illinois at Chicago. He is currently a faculty member at the Harvard Center for Bioethics and a research fellow in the Department of Medicine and the Division of Pharmacoepidemiology & Pharmacoeconomics at the Brigham and Women's Hospital. He previously held a research fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at the University of Oxford.
Clinical trial participants should have a say in new drug pricing
By Spencer Phillips Hey
Stat News. May 18, 2017
Spencer Phillips Hey and Brianna Barsanti-Innes. "Epistemology, Ethics, and Progress in Precision Medicine." Perspectives in Biology and Medicine 59, no. 3 (2016): 293-310. https://muse.jhu.edu/